De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.
about
Growing experience with mTOR inhibitors in pediatric solid organ transplantation.Everolimus in heart transplantation: an update.Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
P2860
De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
De novo therapy with everolimu ...... , multicenter, 12-month study.
@en
De novo therapy with everolimu ...... , multicenter, 12-month study.
@nl
type
label
De novo therapy with everolimu ...... , multicenter, 12-month study.
@en
De novo therapy with everolimu ...... , multicenter, 12-month study.
@nl
prefLabel
De novo therapy with everolimu ...... , multicenter, 12-month study.
@en
De novo therapy with everolimu ...... , multicenter, 12-month study.
@nl
P2093
P2860
P356
P1476
De novo therapy with everolimu ...... , multicenter, 12-month study.
@en
P2093
Carl Grushkin
J Mark Hexham
John D Mahan
Kevin C Mange
Robert Ettenger
P2860
P304
P356
10.1111/PETR.12035
P577
2012-12-28T00:00:00Z